

A STUDY OF RADIOPACITY FOR MAKING BIORESORBABLE METAL/ POLYMER STENTS VISIBLE IN MRI/CT SCAN

Alok Srivastava



**DEPARTMENT OF MECHANICAL ENGINEERING
INDIAN INSTITUTE OF TECHNOLOGY DELHI**

APRIL- 2023

©Indian Institute of Technology Delhi (IITD), New Delhi, 2023

**A STUDY OF RADIOPACITY FOR MAKING
BIORESORBABLE METAL/ POLYMER STENTS
VISIBLE IN MRI/CT SCAN**

by

Alok Srivastava

Department of Mechanical Engineering

Submitted

in fulfillment of the requirements for the degree of Doctor of Philosophy

to the



INDIAN INSTITUTE OF TECHNOLOGY DELHI

APRIL- 2023

Dedications

This thesis is dedicated to my respected parents, adorable sisters, and loving wife Mrs Stuti Srivastava, for taking good care of my little son Mr Kushagra Srivastava during my doctoral study. They believed and stood beside me all the time. My parents gave me free hands to take my discussion without doubting me. Similarly, my wife supported my decision, took good care of me and properly managed the house. They provided me with a positive environment to focus on my doctoral work. Finally, my little champ Kushagra, who was present with me during my journey and his contribution was equally important. We both enjoy the company, this reduces my work stress and makes me more responsible.

Certificate

*This is to certify that the thesis entitled “**A Study of Radiopacity for making Bioresorbable Metal/ Polymer Stents visible in MRI/CT Scan**” submitted by **Mr Alok Srivastava** to the Indian Institute of Technology Delhi for the award of the degree of **Doctor of Philosophy**, is a record of original research work carried out by him. He has worked under our guidance and supervision to fulfill the requirements for submitting the thesis to our knowledge and reaching the requisite standard.*

To the best of my knowledge, the results embodied in this thesis are original and have not been submitted, in part or full, to any other University or Institute for the award of any other Degree or Diploma.

Prof. Naresh Bhatnagar,
Department of Mechanical Engineering,
Indian Institute of Technology Delhi,
Hauz Khas, New Delhi-110016, India

Acknowledgments

Above all, I express gratitude to the Almighty God for everything that has been bestowed upon me.

I would like to express my sincere gratitude from the bottom of my heart to Professor Naresh Bhatnagar for his valuable guidance, constant encouragement, and never-ending unconditional support throughout my doctoral thesis work. During this period, you were my parents and you will remain the same for my whole life. Thank you for motivating me during this entire phase, even when I could not deliver to your expectations. I am thankful for providing me with great mentors to whom I offer my small tribute via this humble acknowledgment.

Before I joined as a Ph.D. scholar, my background was Mechanical-Metallurgist with no experience in biomedical engineering. This work could never have been possible without your never-ending support and mentoring. This entire phase enriched my experience and helped me learn many new things that will benefit my personal and professional growth. Hopefully, I can utilize this knowledge for the betterment of society at large. I feel privileged and very proud to be a student of IIT-Delhi.

I owe sincere gratitude to all my SRC members, Prof. D. Ravi, Prof. Aravindan. S and Prof. Rajesh Prasad for their insightful suggestions and comments. I extend my thanks to all faculty and staff members of Mechanical Engineering for their guidance and generous support.

I wish to express my heartfelt thanks to Dr Pooja Bhati, Dr Shweta Singh, Dr Priya Vashist, Ms Pankaj Chauhan, Mr Avinash Kumar, Ms Ramya Ahuja, Ms Nisha Kumari and Mr Mohit for their technical assistance, fruitful discussion and great help while working as a synergistic team member during my doctoral journey. Thank the seniors, colleagues and lab

mates from the PE lab- Dr Anil Yadav, Dr Hemant Chouhan, Dr Neelanchali Asija, Dr Ashwin Patel, Dr Brig. Sanjay Prasad, Mr Rmakant, Mr Rakesh Bhardwaj, Ms Prajesh Nayak, Ms Aisha Ahmed, Mr Kartik Shukla, Mr Dhruv, Mr Khushi Ram, Mr Makahn, Mr Rajesh Puniya and Mr Madhur. I am thankful to Mr Tulsi Ram, Mr Vijay Tiwari, Ms Tarika Chaddha, Mr Sanjay and Mr Anil from the Production Engineering lab.

I extend my thanks to Mr Shri Ram, a Ph.D. student at IIT Delhi, Applied Mechanics Department to carry out the micro CT analysis of my stent samples. My special thanks to all CRF and NRF staff for carrying out my samples' characterization and for their timely help, especially to Mr Kuldeep Sharma, Mr Mahesh Soni and Ms Aastha Sharma.

Finally, I would like to thank my Family and wife for standing beside me with their love and sacrifices during this journey. My special thanks to my adorable son, whose unconditional love makes my path easy and enjoyable.

Alok Srivastava

Abstract

All bioresorbable polymeric implants are radiolucent, making them undetectable under the X-rays. The high atomic number (at. no.) elements such as Pt, Au, Ta, Ba, or its alloy are attached to a body of bioresorbable polymeric implant to improve their X-ray visibility. However, during the *In Vivo* degradation, these bioinert heavy metals can either detach or leach out from the lesion site and can get accumulated into a vital organ, leading to severe health complications. A novel biodegradable and radiopaque Mg alloy was produced in this research to impart radiopacity to a known biopolymer. Here, Mg metal was alloyed with an optimized ratio of high atomic number elements of Zn and Y, to achieve enough radiographic visibility. The biodegradable radiopaque Mg-Zn-Y alloy contains three phases α -Mg, binary phase Mg_7Zn_3 and Icosahedral (I-phase) $\text{Mg}_3\text{Zn}_6\text{Y}$ precipitated in the inter-dendritic region of α -Mg. The thermally stable intermetallic I-phase particles reinforce the Mg alloy to form in-situ composites.

Mg alloy was powdered and blended in different ratios with bioresorbable Poly-L-lactic acid (PLLA) by using a solvent casting method. The studies were carried out to evaluate the optimum quantity of Mg alloy required in PLLA to achieve not only desirable physicommechanical properties but also radiopacity. The X-ray linear attenuation coefficient (μ) and optical density (OD) were measured from the biocomposite radiographs. Thermal analysis revealed that Mg alloy microparticles acted as a nucleating site and further enhanced the crystallinity of the polymer.

The Mg alloy was further blended in a twin extruder with radiolucent PLLA and Polycaprolactone (PCL) polymer for a comparative study. The bi-axially expanded (BAE) tubes of PLLA/PCL and PLLA/PCL/Mg alloy were extruded for fabricating cardiovascular stents. The potential of 5% Mg alloy microparticles was found to be reinforcing as well as

acting as a radiopaque agent. *In Vitro* cell adhesion and blood compatibility studies were assessed by evaluating the proliferation of L929 fibroblasts and platelets, respectively on the developed blends to ensure complete cytocompatibility.

Furthermore, PLLA/PCL and PLLA/PCL/Mg alloy tubes were smoothly cut to stents. The crimping load, recoil, foreshortening, cyclic loading and unloading were estimated for comparative studies. The proposed biocomposite material thus can improve radiocontrast with enhanced mechanical properties as required for future BVS.

सार

सभी बायोरेसोरेबल पॉलीमरिक इम्प्लांट रेडिओलुकेंट होते हैं, जो उन्हें एक्स-रे के तहत पता लगाने योग्य नहीं बनाते हैं। उच्च परमाणु संख्या (संख्या में) तत्व जैसे कि Pt, Au, Ta, Ba, या इसके मिश्र धातु को उनके एक्स-रे दृश्यता में सुधार करने के लिए बायोरेसोरेबल पॉलीमरिक इम्प्लांट के शरीर से जोड़ा जाता है। हालांकि, इन विवो डिग्रेडेशन के दौरान, ये बायोइन्ट हेवी मेटल या तो अलग हो सकते हैं या घाव वाली जगह से निकल सकते हैं और एक महत्वपूर्ण अंग में जमा हो सकते हैं, जिससे गंभीर स्वास्थ्य जटिलताएं हो सकती हैं। एक ज्ञात बायोपॉलिमर को रेडियोपेसिटी प्रदान करने के लिए इस शोध में एक उपन्यास बायोडिग्रेडेबल और रेडियोपैक एमजी मिश्र धातु का उत्पादन किया गया था। यहाँ, पर्याप्त रेडियोग्राफिक दृश्यता प्राप्त करने के लिए, Zn और Y के उच्च परमाणु संख्या तत्वों के अनुकूलित अनुपात के साथ Mg धातु को मिश्रित किया गया था। बायोडिग्रेडेबल रेडियोपैक Mg-Zn-Y मिश्र धातु में तीन चरण α -Mg, बाइनरी चरण Mg_7Zn_3 और Icosahedral (I-चरण) Mg_3Zn_6Y α -Mg के अंतर-वृक्ष क्षेत्र में अवक्षेपित होते हैं। ऊष्मीय रूप से स्थिर इंटरमेटेलिक I-चरण के कण इन-सीटू कंपोजिट बनाने के लिए Mg मिश्र धातु को सुदृढ़ करते हैं।

सॉल्वेंट कास्टिंग विधि का उपयोग करके Mg मिश्र धातु को अलग-अलग अनुपात में बायोरेसोरेबल पॉली-एल-लैक्टिक एसिड (PLLA) के साथ मिश्रित किया गया था। न केवल वांछनीय भौतिक-यांत्रिक गुण बल्कि रेडियोपेसिटी भी प्राप्त करने के लिए पीएलएलए में आवश्यक

एमजी मिश्र धातु की इष्टतम मात्रा का मूल्यांकन करने के लिए अध्ययन किए गए थे। एक्स-रे रेखिक क्षीणन गुणांक (μ) और ऑप्टिकल घनत्व (OD) को बायोकोम्पोसिट रेडियोग्राफ से मापा गया। थर्मल विश्लेषण से पता चला है कि Mg मिश्र धातु के माइक्रोपार्टिकल्स ने एक न्यूक्लियेटिंग साइट के रूप में काम किया और बहुलक के क्रिस्टलीयता को और बढ़ाया।

एक तुलनात्मक अध्ययन के लिए Mg मिश्रधातु को रेडिओलुकेंट PLLA और पॉलीकैप्रोलैक्टोन (PCL) पॉलीमर के साथ एक जुड़ा हुआ एक्सट्रूडर में मिश्रित किया गया था। कार्डियोवास्कुलर स्टेंट बनाने के लिए PLLA/PCL और PLLA/PCL/Mg Alloy की द्वि-अक्षीय रूप से विस्तारित (बीएई) ट्यूबों को एक्सट्रूड किया गया था। 5% Mg अलॉय माइक्रोपार्टिकल्स की क्षमता प्रबल होने के साथ-साथ रेडियोपैक एजेंट के रूप में कार्य करने वाली पाई गई। विट्रो सेल आसंजन और रक्त संगतता अध्ययनों में विकसित मिश्रणों पर क्रमशः L929 फाइब्रोब्लास्ट्स और प्लेटलेट्स के प्रसार का मूल्यांकन करके पूर्ण साइटोकम्पैटिबिलिटी सुनिश्चित करने के लिए मूल्यांकन किया गया था।

इसके अलावा, PLLA/PCL और PLLA/PCL/Mg अलॉय ट्यूब को स्टेंट में आसानी से काटा गया। तुलनात्मक अध्ययन के लिए क्रिम्पिंग लोड, रिकॉइल, फोरशॉर्टिंग, चक्रीय लोडिंग और अनलोडिंग का अनुमान लगाया गया था। प्रस्तावित बायोकोम्पोसिट सामग्री इस प्रकार भविष्य के बीवीएस के लिए आवश्यक उन्नत यांत्रिक गुणों के साथ रेडियोकॉन्ट्रास्ट में सुधार कर सकती है।

Table of Content

Certificate.....	i
Acknowledgments.....	ii
Abstract.....	iv
List of Figures	xiv
List of Tables.....	xix
List of Abbreviations.....	xx
Chapter-1: Introduction	1
1.1. X-ray imaging in medical digonosis.....	2
1.1.1. Requirement of X-rays visibility: Radiopacity	2
1.1.2. Concept of X-ray and radiopacity	2
1.1.2.1. Bremsstrahlung X-ray.....	3
1.1.2.2. Characteristic X-ray.....	3
1.1.3. Different types of interaction between the X-ray and Material	4
1.1.4. Difference between X-ray Absorption and Attenuation	6
1.1.5. The Role of X-ray Attenuation in the Measurement of Radiopacity	7
1.1.6. Application of radiopacity.....	8
1.1.7. Requirements of Radiopacity in Bioresorbable medical implants	8
1.1.8. Method to Impart Radiopacity in Bioresorbable Polymeric Implants	9
1.2. Limitation of RM in Bioresorbable polymer.....	10
1.3. Concept of Biodegradable Radiopaque Material (BRM).....	11

1.4. Imparting radiopacity in bioresorbable Polymer	12
1.5. Research problem	12
1.6. Research objectives	12
1.7. Scope of the work	13
1.8. The organization of the thesis.....	14
Chapter-2: Literature Review	17
2.1. Atherosclerosis	17
2.2. An implant placed inside the arteries: Stents.....	18
2.3. Evolution of Treatments for Coronary Artery Disease (CAD)	19
2.4. Type of Cardiovascular stents	21
2.4.1. Permanent cardiovascular stents	21
2.4.1.1. Limitation of Permanent Stents	21
2.4.1.2. An alternative to Permanent metallic stents	22
2.4.2. Temporary or Bioresorbable Stents (BRS)	22
2.5. Benefits of Bioresorbable Stents	23
2.5.1. Types of Bioresorbable stents	24
2.5.1.2. Biodegradable Metallic Stents.....	28
2.5.2. Biodegradable Magnesium alloy based Stents.....	28
2.6. Parameters required for producing BRS.....	29
2.6.1. Stent with thin struts.....	30
2.6.2. Extensibility and radial strength.....	31
2.6.3. Mechanism of <i>In Vivo</i> degradation	31
2.6.4. Radiopacity.....	31

2.6.4.1. Radiopaque Marker	32
2.6.4.2. Method to incorporate RM in BRS.....	34
2.6.4.3. The blending of RM with Bioresorbable polymer.....	34
2.6.4.4. Stents coated with RM.....	36
2.6.4.5. Radiopaque polymer-salt complexes.....	37
2.6.4.6. Polymerization products of radiopaque monomers	37
2.6.4.7. Limitation of radiopaque markers	37
2.6.4.8. How to overcome the problem associated with Radiopaque Markers?	38
Chapter-3: Materials and Methods	40
3.1. Production of Biodegradable Radiopaque material (BRM)	40
3.1.1. BRM: Mg-Zn-Y Alloy Characterisation	40
3.2. The blending of Mg alloy microparticles in PLLA	40
3.2.1. Characterization and optimization of Mg alloy in PLLA	41
3.3. Extrusion of PLLA/Mg alloy composite Tube	42
3.3.1. BAE Tubes morphological characterization	44
3.3.2. Fourier Transform Infrared Spectroscopy	45
3.3.3. Differential Thermal Analysis (DTA).....	45
3.3.4. Surface Roughness Analysis	46
3.3.5. Surface Wettability.....	46
3.3.6. Radiopacity Analysis.....	47
3.3.7. Mechanical Test	47

3.3.8. <i>In Vitro</i> Degradation Study	49
3.3.9. <i>In Vitro</i> Biocompatibility study.....	50
3.3.10. <i>In Vitro</i> Blood Biocompatibility study.....	50
3.3.10.1. Hemocompatibility Study.....	50
3.3.10.2. Immuno Assay	51
3.3.10.3. Human Thrombin Anti-Thrombin (HTAT) & Thrombin (HT).....	51
3.3.10.4. Human Fibrinogen (H Frg).....	51
3.4. Fabrication & Testing of the Stent	52
3.4.1. Femtosecond Laser cutting Parameter	52
3.4.2. Stent mechanical behavior	53
3.4.2.1. Radial Recoil after Compression.....	54
3.4.2.2. Radial Recoil after Expansion	54
3.4.2.3. Cyclic radial Loading & unloading test.....	55
3.5. Statistical Analysis	56
Chapter-4: Development and Characterisation of BRM.....	57
4.1. Introduction	57
4.2. Production of Biodegradable Radiopaque Material (BRM).....	57
4.3. Optimization of alloying composition of BRM.....	58
4.4. Additional benefits of BRM	59
4.5. Characterization of BRM: Mg-Zn-Y alloy.....	59
4.5.1. Scanning Electron Microscope (SEM).....	59
4.6. X-Ray Diffraction (XRD) Analysis.....	61

4.7. Differential Thermal Analysis (DTA)	62
4.8. Summary.....	63
Chapter-5: Optimization of Mg alloy content in PLLA	64
5.1. Background.....	64
5.2. Optimization of BRM content in Bioresorbable polymer	65
5.3. Surface Morphology	66
5.4. Radiopacity	67
5.5. Thermal stability.....	68
5.6. <i>In Vitro</i> accelerated degradation study	70
5.6.1. Thermal stability of the degraded sample	72
5.7. Summary.....	75
Chapter-6: Production and Characterization of Bioresorbable BAE Tubes	76
6.1. Background.....	76
6.2. Fabrication of polymeric and biocomposite BAE Tubes	77
6.3. Characterisation of BAE Tubes	78
6.4. Fourier Transform Infrared Spectroscopy (FTIR).....	79
6.5. Surface Roughness Analysis	80
6.6. Wettability Test	81
6.7. Differential Thermal Analysis (DTA)	82
6.8. Mechanical Test.....	83
6.8.1. Tensile Properties	84
6.8.2. Radial property and Cyclic loading.....	85
6.8.3. Bending properties	86
6.9. Radiopacity Analysis	87

6.10.	<i>In Vitro</i> Degradation Study	88
6.11.	<i>In Vitro</i> study Biocompatibility	92
6.12.	<i>In Vitro</i> Blood Biocompatibility study	94
6.12.1.	Hemocompatibility Study	94
6.12.2.	Immuno Assay.....	95
6.13.	Summary	96
Chapter-7: Fabrication and Characterisation of the Cardiovascular Stent.....		97
7.1.	Stent Design.....	97
7.2.	Femtosecond Laser cutting parameter	98
7.2.1.	Morphological analysis of femtosecond laser-treated stent	99
7.3.	Radiopacity.....	100
7.4.	Mechanical Properties of Stent.....	101
7.4.1.	Radial Compressive Test.....	102
7.4.1.1.	Crimping Recoil (R_c).....	103
7.4.1.2.	Expansion Recoil.....	104
7.4.2.	Cyclic Radial Compression Loading.....	105
7.5.	Summary.....	107
Chapter-8: Conclusions and Future Work		108
Publications made out of Thesis Work.....		145
Brief Bio-Data		148

List of Figures

Figure 1.1: The X-ray spectrum- a combination of Characteristic & Bremsstrahlung. radiation. [16].	3
Figure 1.2: Different ways of interaction of X-rays with materials [17].	4
Figure 1.3: X-ray image of hands, where white color indicates finger bones, the partially grey color corresponds to tissue or muscles, whereas black is the air around the hands from where X-rays can pass without any interaction [24].	6
Figure 1.4: X-ray attenuation depends on the Photoelectric and Compton effects.	7
Figure 1.5: Different types of X-ray scattering and methods used for X-ray diagnosis.	7
Figure 1.6: a) Comparison of X-ray visibility in various bioresorbable cardiovascular stents [30] & b) comparing radiopacity of metallic stent & gold markers.	9
Figure 1.7: Different methods adopted to impart radiopacity in the polymers [32]–[35].	10
Figure 1.8: Systematic flow chart of the present thesis work.	16
Figure 2.1: Stent used in cardiovascular arteries [39].	17
Figure 2.2: a) Cardiovascular stent design parameter & b) showing markers at the ends of a stent [43].	18
Figure 2.3: The flow diagram shows the evolution of treatments for Coronary Artery Disease (CAD) [48].	20
Figure 2.4: a) Deployment of stent to compress the plaque & b) endothelization process [53].	21
Figure 2.5: Bioresorbable stents under clinical or pre-clinical investigation [68].	25
Figure 2.6: Biodegradable metallic stent [85].	28
Figure 2.7: The Magmaris [®] scaffold created by Biotronik uses SynerMag [®] magnesium alloy as the structural backbone of the stent [91].	29
Figure 2.8: a) Radiopaque marker embedded on the stent, b) Integrated stent markers, stent without markers and the X-ray visibility window of background without a stent [95] [98].	33

Figure 3.1: Schematic layout for production of Mg alloy and PLLA/BRM films.	41
Figure 3.2: The process flow diagram for producing bioresorbable radiopaque stents.	43
Figure 3.3: BAE tube extrusion where the radial force was exerted by compressed air and longitudinal force was applied by caterpillar rpm.	44
Figure 3.4: a) Crucible used to hold the sample & b) the DTA equipment used for both DSC and TGA analysis.	45
Figure 3.5: a) Optical surface profilometer & b) shows the mounting of BAE tubes and stylus over it use to estimates the surface roughness.	46
Figure 3.6: Contact angle measurement equipment from Krüss® DSA100S.	47
Figure 3.7: a) μ CT scan from Scano Medical & b) showing slot for sample holder.	47
Figure 3.8: a) UTM Instron© & b) Pin Fixture to hold the tube and avoid crushing.	48
Figure 3.9: a) Radial crimping machine & b) Crimping jaw used for radial compression. ...	48
Figure 3.10: a) Bose dynamic force testing machine & b) Bending test perform on tubes.	49
Figure 3.11: a) Water Bath, b) Sample kept in the PBS & c) Degraded Samples.	50
Figure 3.13: a) Femtosecond laser from Coherent® & b) showing Laser tip and tube holder.	53
Figure 3.12: a) Banbros Vision measurement machine & b) Olympus Stereo Microscope. microscope.	53
Figure 3.14: a) Catheter purchased from Newtech®, b) Titanium balloon Catheter & c) Digital Microscope from Keyence®.	54
Figure 3.15: a) Polymeric Balloon, b) Stent mounted on balloon Catheter, c) Plunger to inflate and deflate ballon & d) Crimped and Expanded Stent.	55
Figure 4.1: Production of Bioresorbable radiopaque Mg-Zn-Y Alloy.	58
Figure 4.2: Radiographic image of Mg alloy, white color represents radiopaque, whereas black or grey is radiolucent material.	58
Figure 4.3: SEM microstructure with EDS analysis was used for elemental distribution- a) indicate different phases present in Mg-Zn-Y alloy, b) represent α -Mg phase, c) Mg-Zn binary phases and d) Intermetallic ternary phase precipitated in the interdendritic region of primary Mg phase.	60

Figure 4.4: XRD patterns of as-cast Mg-Zn-Y alloy.....	61
Figure 4.5: The DSC and TGA thermograph of as-cast Mg-Zn-Y alloy powder.....	62
Figure 5.1: a) SEM image of Mg alloy microparticles of size 20-25 microns & b) BRM (%) addition in PLLA polymer.	65
Figure 5.2: (a-e) show surface morphologies of PLLA with (0, 5, 15, 25 & 50% wt.) of Mg alloy f) SEM at 5000X indicate that microparticles blended with the matrix without any defects or agglomeration, g) Mapping of Mg particle (red color) indicate the distribution of alloy inside the PLLA matrix & h) EDX analysis showing BRM in the PLLA.....	66
Figure 5.3: μ CT-Scan of different materials where white color indicates BRM particles a) Pure PLLA, b) PLLA/BRM (5%), c) PLLA/BRM (15%), d) PLLA/BRM (25%), e) PLLA/BRM (50%), f) Pure BRM & g) Comparision between the OD of materials.	67
Figure 5.4: a) DSC and b) TGA thermograph of PLLA/BRM biocomposite for different addition ratios were compared with neat PLLA.....	69
Figure 5.5: a) In Vitro accelerated degradation process for biocomposite, b) pH variation for 0, 5, 15, 25 and 50% of BRM addition in PLLA with immersion time & c) Weight loss vs the amount of BRM content in PLLA.	72
Figure 5.6: Degradation process of PLLA, where water molecules get quickly diffused inside the amorphous region and break them as compared to the crystalline phase.	73
Figure 5.7: Graph showing the relationship between first-order rate constant and Mg alloy content in the polymer (* $p < 0.05$).	74
Figure 6.1: a) Blending process on the Twin extruder and chopping of the filaments , b)BAE tube extrusion process on Single screw extruder and cutting of BAE Tubes & c) Cold storage to keep BAE tubes.	77
Figure 6.2: a) & c) is the BAE tubes, whereas b) & d) is the stent cut out from the tube.	78
Figure 6.3: Polymeric and composite BAE Tubes were used for comparative studies.	79
Figure 6.4: FTIR spectra of BAE tube for PLLA/PCL blend polymer and PLLA/PCL/BRM..	80

Figure 6.5: Arithmetic mean of surface roughness (R_a) and the largest profile peak height above the mean line within the sampling length (R_p) was estimated for a) smooth polymeric tube & b) micro-rough composite tube.	80
Figure 6.6: The static water contact angle (Θ) measured on the polymeric & composite tubes.	82
Figure 6.7: Thermal curves of polymer & composite BAE Tubes: a) DSC curve and b) TGA thermographs.....	82
Figure 6.8: a) Tensile stress Vs strain graph for polymeric & composite tube, b) represent SEM micrograph of composite fractured surface confirm the proper bonding between matrix & reinforced Mg alloy microparticles.	84
Figure 6.9: Graph comparing a) Radial property and b) cyclic loading and unloading.	85
Figure 6.10: Three-point bending force-deflection curve of the polymeric & composite tubes.	86
Figure 6.11: μ CT-Scan of composite tube, where the black color indicates air in the chamber, grey colour represents polymer casing & paper roll used to support the tube. The white particles are BRM embedded inside the polymer, making it visible on a radiograph.....	87
Figure 6.12: a) In Vitro degradation steps explained for biocomposite b) shows pH variation and c) weight loss of sample, whereas in figures c(i) & (ii) illustrates the condition of the degraded tubes at different time intervals.	89
Figure 6.13: SEM micrographs of In vitro degraded BAE tubes at different time intervals i.e. 1 st , 3 rd , 5 th and 7 th days. Here, a), c), e), f) represents the polymer and b), d), f), g) corresponds to the bio-composite.....	91
Figure 6.14: MTT Assay test of composite material, the cell culture was performed directly on the PLLA/Mg alloy (5%) and compared with the control. The cell incubation period was maintained for 1, 3 and 7 days.	92
Figure 6.15: Cell morphology of L929 fibroblasts seeded on the PLLA/PCL and PLLA/PCL/BRM flat BAE tubes after 1 st day- a) & b), 3 rd day- c) & d) and 7 th days of incubation- e) & f).	93
Figure 6.16: Hemolysis Analysis (n=3) of polymer & composite samples (* $p < 0.05$).	94

<i>Figure 6.17: Graph between Concentration Vs Coagulating Factors for different materials.</i>	96
<i>Figure 7.1: Polymeric stent design showing various design parameters.</i>	97
<i>Figure 7.2: a) Extruded Composite BAE tubes, b) Composite stents cut using the Femtosecond Laser machine & c) Optimized laser parameters.</i>	98
<i>Figure 7.3: a) SEM image of a composite stent, b) & c) the top and cross-sectional topography of a stent surface, respectively and d) micrograph of a cut edge at 2.5 kX magnification.....</i>	100
<i>Figure 7.4: Permanent markers attached at the end of the bioresorbable polymeric stent, making it detectable on radiographic film. During the In Vivo degradation process, it can flake or detach from the body of a stent, causing serious health concerns.</i>	101
<i>Figure 7.5: a) Illustration of the radiopaque implant & b) μ-CT-Scan: Cross-sectional view of a composite stent.</i>	101
<i>Figure 7.6: a) Graph shows the radial force required for crimping the stents, b) indicates the flexibility of composite is higher than polymer & c) Stent before & after crimping.</i>	102
<i>Figure 7.7: Stent was crimped from 3 mm to 1.1 mm and held for 60 s at 1.1mm.</i>	103
<i>Figure 7.8: Expanded recoil for different stent materials.</i>	105
<i>Figure 7.9: Graphs a) and b) represent the effect of radial loading and unloading on different stents material after 1st, 500th and 1000th cycles.</i>	106

List of Tables

<i>Table 2.1: Companies produce the next-generation Bioresorbable stents [49]–[51].</i>	20
<i>Table 2.2: Mechanical and physical characteristics of stent materials [58]–[60].</i>	23
<i>Table 2.3: Summary of various bioresorbable/biodegradable stents [69]–[71].</i>	26
<i>Table 2.4: Materials with their Effective Atomic number and Linear Attenuation [94].</i>	32
<i>Table 2.5: Study on the blending of radiopaque materials in the bioresorbable polymer.</i>	34
<i>Table 3.1: Heating zone (°C) of Single screw extrusion for producing BAE tubes.</i>	43
<i>Table 5.1: DSC and TGA data of PLLA with different addition ratios of Mg alloy.</i>	69
<i>Table 5.2: DSC/TGA analysis of degraded composites at different immersion times.</i>	74
<i>Table 6.1: Heating zone (°C) of Single extrusion for producing BAE tubes.</i>	77
<i>Table 6.2: DSC and TGA data of PLLA/PCL and PLLA/PCL/Mg alloy.</i>	83
<i>Table 6.3: Tensile properties of BAE Tubes.</i>	84
<i>Table 7.1: The optimization of cardiovascular polymeric stent design [238].</i>	98
<i>Table 7.2: Femtosecond laser cutting parameter for the BAE tube.</i>	99
<i>Table 7.3: Crimping of a stent at two different temperatures and holding time.</i>	104

List of Abbreviations

BAE: Bi-axially Expanded

BRM: Biodegradable Radiopaque Material

BRS: Bioresorbable radiopaque Stent

BVS: Bioabsorbable Vascular Stent

CAD: Coronary Artery Disease

CVD: Cardiovascular diseases

DCM: Dichloromethane

DES: Drug-eluting stent

D_r: Degradation rate

DSC: Differential scanning calorimetry

DTA: Differential Thermal Analysis

d_c^a & d_e^a : Diameter of a stent after crimping and expansion, respectively

d_e: Expanded Stent diameter

EDS: Energy dispersive spectrometer

ELISA: Enzyme-linked immunoassay kit

ϵ_c^p : Plastic strain of composite, ϵ_p^p : Plastic strain of polymer

e⁻: Electron, eV: Electron volt

FTIR: Fourier Transform Infrared Spectroscopy

HU: Hounsfield Number

H: Hemolysis

H Frg: Human Fibrinogen

HT & HTAT: Thrombin & Human Thrombin Anti-Thrombin, respectively

I₀: Incident X-ray beam intensity, I_s: Transmitted X-ray beam intensity

K_{α} & K_{β} : vacancy in the K shell filled by an electron from the L & M shell, respectively

MRI: Magnetic resonance imaging

MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide

OD: Optical Density

PBS: Phosphate buffer saline

PCI: Percutaneous coronary intervention

PCL: Polycaprolactone

PLLA: Poly-L-lactide

PPP & PRP: Platelet-Poor Plasma & Platelet-Rich Plasma

R_a & R_p : Average and Peak surface roughness

RM: Radiopaque Material

SEM: Scanning electron microscope

TGA: Thermal gravimetric analysis

T_g & T_m : Glass Transition temperature & Melting Point, respectively

U_C^d & U_P^d : Stain energy dissipated in composite & Polymer, respectively

XRD: X-ray Diffraction

UV: Ultraviolet Rays

Z_{eff} : Effective Atomic Number

λ & λ' : Wavelength of Incident & Transmitted X-ray

θ : Contact Angle

α : Primary Phase

ω : Weight Fraction

μ : Linear Attenuation coefficient

μ CT: Micro Computed Tomography

χ_c : Degree of Crystallinity